Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies

Author(s): Ying Li, Chen-Fu Liu and Guo-Wu Rao*

Volume 28 , Issue 8 , 2021

Published on: 12 March, 2020

Page: [1565 - 1584] Pages: 20

DOI: 10.2174/0929867327666200312113011

Price: $65

Abstract

Poly (ADP-ribose) polymerase (PARP) acts as an essential DNA repair enzyme. PARP inhibitors are novel small molecule targeted drugs based on the principle of "Synthetic Lethality", which affect DNA repair process by competitively inhibiting the activity of PARP enzyme and thereby kill cancer cells. Currently, four PARP inhibitors including olaparib, rucaparib, niraparib, and talazoparib have been approved by FDA for cancer treatment and have achieved great success in the treatment of ovarian cancer, breast cancer, and pancreatic cancer, etc. This paper provides a general overview of the research progress of PARP inhibitors including the major structure types, structure-activity relationship (SAR), and synthetic routes, with the aim of providing ideas for the discovery and synthesis of novel PARP inhibitors.

Keywords: Ovarian cancer, synthetic lethality, PARP inhibitors, olaparib, structure-activity relationship, phthalazinones, synthesis.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy